Dear reader of ADxS.org, please excuse the disruption.

ADxS.org needs about $63500 in 2024. In 2023 we received donations of about $ 32200. Unfortunately, 99.8% of our readers do not donate. If everyone who reads this request makes a small contribution, our fundraising campaign for 2024 would be over after a few days. This donation request is displayed 23,000 times a week, but only 75 people donate. If you find ADxS.org useful, please take a minute and support ADxS.org with your donation. Thank you!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V..

$8975 of $63500 - as of 2024-02-29
14%
ADxS.org Logo
ADxS.org Logo
Search Donations Addresses Recent changes ADHS-Forum Deutsche Version
Register

Already have an account? Login

Header Image
Levophacetoperane for ADHD

Sitemap

The ADxS.org project
Abstract from ADxS.org
Symptoms
Consequences of ADHD
Origin
Stress
Neurological aspects
Diagnostics
Prevention
Treatment and therapy
Medication for ADHD - Overview
Choice of medication for ADHD or ADHD with comorbidity
Dosing of medication for ADHD
Suitable medication for ADHD
Experimental medication for ADHD
Sleep disorder-related medication for ADHD
Appetite-enhancing medication for ADHD
Medication for ADHD in development
Less suitable medication for ADHD
Vitamins, minerals, dietary supplements for ADHD
Plant extracts for ADHD
Medication and drugs - the difference
Substance abuse with self-medication effect in ADHD
Addresses
This and that about ADHD
Tests and surveys
Forum

Levophacetoperane for ADHD

Previous page Next page

Levophacetoperane1

Other names: NLS-3 or (R, R)-enantiomer of phacetoperane
Brand name: Lidepran® (8228 R.P.)

Levophacetoperane is the reverse ester of methylphenidate.
It was marketed in Canada and Europe in the late 1950s for the treatment of ADHD, obesity and depression.

(Levo-)phacetoperane differs from other stimulants in its effect on the catecholamine system and showed a favorable risk-benefit ratio.
It has been in extensive clinical use in almost a thousand children and adolescents. It was found to have fewer side effects than comparable stimulant treatments in large dose ranges.

  1. Konofal E, Lecendreux M, Bizot JC, Lormier AT, Figadere B (2023): NLS-3 (Levophacetoperane or (R,R) Phacetoperane): A Reverse Ester of Methylphenidate: A Literature Review. Curr Med Chem. 2023 Jan 20. doi: 10.2174/0929867330666230120161837. PMID: 36683369. REVIEW ↥

Diese Seite wurde am 04.04.2024 zuletzt aktualisiert.
Previous page Next page